Aberrant canonical NF-κB pathway activation in DLBCL attributes a significant fraction of the presence of oncogenic mutations in genes [88–90]; however, the previously published paper reveals that up to 15% of DLBCLs have genetic mutations activating the alternative NF-κB pathway. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.